10 officials in Karnataka win awards

Inspiration/ Positive News and Features, Records, All

The State government has selected 10 of its employees for the Sarvothama Seva Awards for their services in the year 2020-21.

Of the 10 employees, six are working in various departments in Bengaluru.

The award winners are: R. Chandrashekar, deputy secretary, DPAR, Cabinet division, Vidhana Soudha, Bengaluru; Gangaram, Panchayat Development Officer, Doddajala Gram Panchayat, Yelahanka; B.N. Girish, tahsiladar, Davangere taluk; Basavalingaiah R. Hiremath, Assistant Commissioner, Excise, Bengaluru; G. Harsha, first division assistant, Advocate General’s office, High Court, Bengaluru; H.P. Hemavathi, nursing officer, C.V. Raman Government Hospital, Indiranagar, Bengaluru; M. Anjaneya, senior health assistant, district medical officer’s office, Kudligi, Vijayanagara; Chandramathi M. Hegde, nursing officer, grade II, McGann Hospital, Shivamogga; T.S. Latha, PR officer, KSRTC, Bengaluru; and Chandrashekar Nayak, deputy director, Deputy Commissioner’s office building, Manipal, Udupi.

The award winners will be given a cash prize of ₹25,000 each and a certificate.

source: http://www.thehindu.com / The Hindu / Home> News> States> Karnataka / by Special Correspondent / Bengaluru -April 25th, 2021

Free vaccination for those in 18-44 age group in govt. centres

Inspiration/ Positive News and Features, Leaders, Records, All, Resources of Free Materials, Science & Technology, World Opinion
Chief Minister B.S. Yediyurappa  

Karnataka on Monday announced free vaccination for COVID-19 for all those aged between 18 and 44 in government hospitals and centres from May 1.

Health Minister K. Sudhakar said ₹400 crore had so far been allocated for the purpose.

The government has been providing free vaccination to all those aged above 45 in government facilities, though there have been multiple complaints of vaccine shortage. Asked about vaccine availability, he said stocks based on orders were yet to come and more details would be released soon.

At a press conference on Monday, after the Chief Minister announced the decision, Dr. Sudhakar said with third and fourth waves being seen in other countries, the need was to vaccinate as many people as possible as soon as possible. “A sum of ₹81.32 crore has been allocated for COVID-19-related medicines, and ₹28 crore for Remdesivir,” he added.

source: http://www.thehindu.com / The Hindu / Home> News> States> Karnataka / by Staff Reporter / Bengaluru – April 27th, 2021

Biocon Biologics, Viatris receive approval for cancer drug

Business & Economy, Records, All, Science & Technology, World Opinion

Synopsis

Abevmy is approved for treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.

Biocon Biologics has received approval for its cancer drug Abevmy co-developed with Viatris.

Abevmy 100 & 400 mg, a biosimilar of Bevacizumab has received marketing authorization approval from the European Commission (EC) following the positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, said the company in a filing to the stock exchange.

Abevmy is approved for treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.

The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.

“The European Commission’s approval of our biosimilar Bevacizumab will enable us to offer this biologic therapy to cancer patients in the EU along with our partner Viatris. The addition of biosimilar Bevacizumab will strengthen our portfolio of biosimilars for cancer in the EU, which include biosimilar Trastuzumab and biosimilar Pegfilgrastim. This approval underlines our commitment to expand affordable access to life-saving biosimilars and make an enduring impact on global health,” said a company spokesperson.

source: http://www.economictimes.indiatimes.com / The Economic Times / Home> Business News> India> Healthcare> Biotech>Pharmaceuticals / ET Bureau / April 26th, 2021